Bionova Scientific, a biologics CDMO with deep protein production, cell line development, process development and analytical expertise, has initiated construction of its new biologics manufacturing facility. Construction will be completed in approximately 10 months, with commissioning scheduled for Q3 2021.
The 36,000 sq. ft. facility will utilize single-use technologies for all core unit operations and is designed to accommodate two 2000L mammalian cell culture trains, capable of producing clinical and commercial bulk drug substance. Located within Bionova’s headquarters, the plant is optimized for multi-product manufacturing of monoclonal antibodies and other recombinant proteins. Bionova has partnered with industry leaders DGA and Dome Construction for design and construction.
Bionova Founder and CEO Amy Kong said, “Thanks to an equity investment in 2019 by Great Point Partners and several months of detailed planning by our team, today marks an important step in Bionova’s path forward. We are grateful to our excellent clients and partners for their support and guidance as we build-out this new capability.”
“Despite the disruptions of this year, we have continued to add capabilities to support client programs. Earlier, we expanded our high-throughput automation infrastructure to support process characterization studies and process development programs,” Bionova co-founder and COO Chung Chun added. “Today’s initiation of the GMP facility build-out will redefine the scope of services we can offer to the biotherapeutics industry. It will also help to fill the growing need for industry biomanufacturing capacity.”